Adhesive Tape Trauma Evaluation of Two Gentle Tapes
Adhesive Tape Trauma Evaluation of Two Gentle Tapes in Healthy Human Infant Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Broomall, Pennsylvania, United States, 19008
- cyberDERM
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Who are healthy and who have intact skin at the test site with a baseline score of 0 for erythema
- Who are between the ages of 6 months - 4 years of age
- Who has a Fitzpatrick Skin Type of I, II or III
- Subject who's parent agrees to not use any products (i.e. topical medications, creams, powders or ointments) on the test sites for 24 hours prior to the study start date
- Whose parent is willing to sign the Informed Consent Form.
Exclusion Criteria:
- Who are known to be developmentally delayed
- Who have sunburn, skin infection or scars, moles, or other blemishes on the back that would obscure grading of the test sites
- Who have had any exposure to other topical medications, creams, powders, or ointments on the test sites 24 hours prior to the start of the study.
- Who have had a strep infection within the past 2 weeks
- Who have a history of diabetes, psoriasis, any active dermatitis, or recent history of dermatitis or skin reactions
- Who have allergies to isocyanates, or acrylate adhesive products
- Who currently take any antihistamines or anti-inflammatory medication or who have taken any of these medications within 48 hours prior to the start of the study or does not agree to refrain from taking these medications for the 48 hours prior to the start of the study and for the duration of the study (Tylenol is an acceptable pain reliever).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 3M Kind Removal Silicone Tape
investigational medical Silicone tape, 1" x 1.5" sample, applied on time, worn for 24 hours.
|
Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
Other Names:
|
|
Other: 3M Micropore Medical Tape
Commercially available Medical Paper Tape, 1" x 1.5" sample, applied on time, worn for 24 hours.
Study Control.
|
Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin Trauma
Time Frame: 24 hours
|
Expert grader using Erythema/Edema Scale 0=No visible response
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Gary L Grove, PhD, cyberDERM
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EM-05-012247
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.